February 6th 2025
More excellent responses occurred for patients with low-risk thyroid cancer who had thyroidectomies without radioiodine vs treatment with radioiodine.
September 11th 2024
2025 GU Satellite Symposia in San Francisco
February 13-14, 2025
Register Now!
Medical Crossfire®: Real World Strategies to Improve Therapeutic Durability and Outcomes in CLL
February 20, 2025
Register Now!
Virtual Testing Board: Digging Deeper on Your Testing Reports to Elevate Patient Outcomes in Advanced Non-Smal...
February 27, 2025
Register Now!
The Evolving Tool Box in Advanced HR+/HER2– Breast Cancer: What You Need to Know About Next-Generation SERDs, PI3K/AKT, ADCs, CDK4/6 and Beyond…
View More
18th Annual New York GU Cancers Congress™
March 28-29, 2025
Register Now!
Coffee Talk™: Navigating the Impact of HER2/3, TROP2, and PARP from Early Stage to Advanced Breast Cancer Care
View More
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
26th Annual International Lung Cancer Congress®
July 25-26, 2025
Register Now!
20th Annual New York Lung Cancers Symposium®
November 15, 2025
Register Now!
Community Practice Connections™: 6th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Cases & Conversations™: Integrating Novel Approaches to Treatment in First-line ALK+ mNSCLC – Enhancing Patient Outcomes with Real World Multidisciplinary Strategies
View More
Community Practice Connections™: Case Discussions in TNBC… Navigating the Latest Advances and Impact of Disparities in Care
View More
Annual Hawaii Cancer Conference
January 24-25, 2026
Register Now!
5-Year Findings Support Xevinapant Plus Chemotherapy in Locally Advanced Head and Neck Cancer
October 28th 2022A presentation at the 2022 ESMO Congress found that xevinapant plus chemoradiotherapy decreased the risk of death by twice that of placebo for patients with unresectable, locally advanced head and neck squamous cell carcinoma.
FDA Approves Additional Cetuximab Dose for KRAS Wild-Type, EGFR-Expressing CRC, Head and Neck Cancer
April 7th 2021The FDA has approved a new biweekly dosing regimen of 500 mg/m2 as a 120-minute intravenous infusion for cetuximab (Erbitux) for patients with KRAS wild-type, EGFR-expressing colorectal cancer or squamous cell carcinoma of the head and neck.
Tipifarnib Gets Breakthrough Therapy Designation for HRAS-Mutated HNSCC
February 25th 2021The FDA has granted a breakthrough therapy designation to tipifarnib for use in patients with recurrent or metastatic HRAS-mutated head and neck squamous cell carcinoma with variant allele frequency of 20% or higher following progressive disease on platinum-based chemotherapy.
Nivolumab Plus Chemotherapy Improves Survival Outcomes in Gastric and Esophageal Cancers
August 13th 2020Nivolumab in combination with chemotherapy as a frontline treatment demonstrated a significant survival benefit in patients with metastatic gastric cancer, gastroesophageal junction cancer, or esophageal adenocarcinoma.
FDA Expands Gardasil 9 Approval for HPV-Related Cancers
June 15th 2020On Friday, the FDA expanded the approval for Gardasil 9 for the prevention of oropharyngeal and other head and neck cancers caused by human papillomavirus (HPV) types 16,18,31, 33, 45, 52, and 58, according to Merck, the manufacturer of the vaccine.